Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells von André, Pascale, Denis, Caroline, Soulas, Caroline, Bourbon-Caillet, Clarisse, Lopez, Julie, Arnoux, Thomas, Bléry, Mathieu, Bonnafous, Cécile, Gauthier, Laurent, Morel, Ariane, Rossi, Benjamin, Remark, Romain, Breso, Violette, Bonnet, Elodie, Habif, Guillaume, Guia, Sophie, Lalanne, Ana Ines, Hoffmann, Caroline, Lantz, Olivier, Fayette, Jérôme, Boyer-Chammard, Agnès, Zerbib, Robert, Dodion, Pierre, Ghadially, Hormas, Jure-Kunkel, Maria, Morel, Yannis, Herbst, Ronald, Narni-Mancinelli, Emilie, Cohen, Roger B., Vivier, Eric

Volltext

Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers von Ortiz-Cuaran, Sandra, Bouaoud, Jebrane, Karabajakian, Andy, Fayette, Jérôme, Saintigny, Pierre

Volltext

Induction chemotherapy in head and neck cancers: Results and controversies von Gau, Max, Karabajakian, Andy, Reverdy, Thibaut, Neidhardt, Eve-Marie, Fayette, Jérôme

Volltext

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer von Borghaei, Hossein, Paz-Ares, Luis, Horn, Leora, Spigel, David R, Steins, Martin, Ready, Neal E, Chow, Laura Q, Vokes, Everett E, Felip, Enriqueta, Holgado, Esther, Barlesi, Fabrice, Kohlhäufl, Martin, Arrieta, Oscar, Burgio, Marco Angelo, Fayette, Jérôme, Lena, Hervé, Poddubskaya, Elena, Gerber, David E, Gettinger, Scott N, Rudin, Charles M, Rizvi, Naiyer, Crinò, Lucio, Blumenschein, George R, Antonia, Scott J, Dorange, Cécile, Harbison, Christopher T, Graf Finckenstein, Friedrich, Brahmer, Julie R

Volltext

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 0... von Horn, Leora, Spigel, David R, Vokes, Everett E, Holgado, Esther, Ready, Neal, Steins, Martin, Poddubskaya, Elena, Borghaei, Hossein, Felip, Enriqueta, Paz-Ares, Luis, Pluzanski, Adam, Reckamp, Karen L, Burgio, Marco A, Kohlhäeufl, Martin, Waterhouse, David, Barlesi, Fabrice, Antonia, Scott, Arrieta, Oscar, Fayette, Jérôme, Crinò, Lucio, Rizvi, Naiyer, Reck, Martin, Hellmann, Matthew D, Geese, William J, Li, Ang, Blackwood-Chirchir, Anne, Healey, Diane, Brahmer, Julie, Eberhardt, Wilfried E E

Volltext

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related qua... von Harrington, Kevin J, Ferris, Robert L, Blumenschein, George, Colevas, A Dimitrios, Fayette, Jérôme, Licitra, Lisa, Kasper, Stefan, Even, Caroline, Vokes, Everett E, Worden, Francis, Saba, Nabil F, Kiyota, Naomi, Haddad, Robert, Tahara, Makoto, Grünwald, Viktor, Shaw, James W, Monga, Manish, Lynch, Mark, Taylor, Fiona, DeRosa, Michael, Morrissey, Laura, Cocks, Kim, Gillison, Maura L, Guigay, Joël

Volltext

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have... von Zandberg, Dan P., Algazi, Alain P., Jimeno, Antonio, Good, James S., Fayette, Jérôme, Bouganim, Nathaniel, Ready, Neal E., Clement, Paul M., Even, Caroline, Jang, Raymond W., Wong, Stuart, Keilholz, Ulrich, Gilbert, Jill, Fenton, Moon, Braña, Irene, Henry, Stephanie, Remenar, Eva, Papai, Zsuzsanna, Siu, Lillian L., Jarkowski, Anthony, Armstrong, Jon M., Asubonteng, Kobby, Fan, Jean, Melillo, Giovanni, Mesía, Ricard

Volltext

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma von Wildsmith, Sophie, Li, Weimin, Wu, Song, Stewart, Ross, Morsli, Nassim, Raja, Rajiv, Zhang, Qu, Ye, Jiabu, He, Philip, Shetty, Jagdish, Yovine, Alejandro, Holoweckyj, Nicholas, Real, Katia, Walker, Jill, Wrona, Magdalena, de Los Reyes, Melissa, Barker, Craig, Whiteley, Jessica, Haddad, Robert, Licitra, Lisa, Ferris, Robert, Fayette, Jérôme, Zandberg, Dan P, Siu, Lillian L, Mesía, Ricard

Volltext

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients von Foy, Jean-Philippe, Karabajakian, Andy, Ortiz-Cuaran, Sandra, Boussageon, Maxime, Michon, Lucas, Bouaoud, Jebrane, Fekiri, Dorssafe, Robert, Marie, Baffert, Kim-Arthur, Hervé, Geneviève, Quilhot, Pauline, Attignon, Valéry, Girod, Angélique, Chaine, André, Benassarou, Mourad, Zrounba, Philippe, Caux, Christophe, Ghiringhelli, François, Lantuejoul, Sylvie, Crozes, Carole, Brochériou, Isabelle, Pérol, Maurice, Fayette, Jérôme, Bertolus, Chloé, Saintigny, Pierre

Volltext

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity von Karabajakian, Andy, Bouaoud, Jebrane, Michon, Lucas, Kamal, Maud, Crozes, Carole, Zrounba, Philippe, Auclair-Perossier, Jessie, Gadot, Nicolas, Attignon, Valéry, Le Tourneau, Christophe, Benzerdjeb, Nazim, Fayette, Jérôme, Saintigny, Pierre

Volltext

Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis von Bay, Jacques‐Olivier, Ray‐Coquard, Isabelle, Fayette, Jérôme, Leyvraz, Serge, Cherix, Stephane, Piperno‐Neumann, Sophie, Chevreau, Christine, Isambert, Nicolas, Brain, Etienne, Emile, Georges, Le Cesne, Axel, Cioffi, Angela, Kwiatkowski, Fabrice, Coindre, Jean‐Michel, Bui, Nguyon Binh, Peyrade, Frédéric, Blay, Jean‐Yves

Volltext

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised... von Harrington, Kevin, Berrier, Alain, Robinson, Martin, Remenar, Eva, Housset, Martin, de Mendoza, Fernando Hurtado, Fayette, Jérôme, Mehanna, Hisham, El-Hariry, Iman, Compton, Natalie, Franklin, Natalie, Biswas-Baldwin, Nigel, Lau, Mike, Legenne, Philippe, Kumar, Rejnish

Volltext

Occupational asbestos exposure and survival among lung cancer patients von Noelle, Hugo, Pérol, Olivia, Pérol, Maurice, Avrillon, Virginie, Belladame, Elodie, Fayette, Jérôme, Fournié, Françoise, Swalduz, Aurélie, Dessemon, Juliette, Blay, Jean-Yves, Neidhardt, Eve-Marie, Saintigny, Pierre, Tabutin, Mayeul, Boussageon, Maxime, Praud, Delphine, Charbotel, Barbara, Fervers, Beatrice

Volltext

Chemotherapy for recurrent/metastatic head and neck cancers von Karabajakian, Andy, Toussaint, Philippe, Neidhardt, Eve-Marie, Paulus, Valérie, Saintigny, Pierre, Fayette, Jérôme

Volltext

Prognostic impact of extranodal extension in resected head and neck squamous cell carcinomas in the era of postoperative chemoradiation: A retrospective monocentric study von Gau, Max, Fonseca, Aurélien, Ozsahin, Mahmut, Fayette, Jérôme, Poupart, Marc, Roux, Pierre-Eric, Schütz, Frédéric, Zrounba, Philippe, Grégoire, Vincent

Volltext

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma von Seiwert, Tanguy Y., Wildsmith, Sophie, Fayette, Jérôme, Harrington, Kevin, Gillison, Maura, Ahn, Myung-Ju, Takahashi, Shunji, Weiss, Jared, Machiels, Jean-Pascal, Baxi, Shrujal, Baker, Valerie, Evans, Brent, Morsli, Nassim, Jill Walker, Real, Katia, L’Hernault, Anne, Psyrri, Amanda

Volltext

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) von Fayette, Jérôme, Wirth, Lori, Oprean, Cristina, Udrea, Anghel, Jimeno, Antonio, Rischin, Danny, Nutting, Christopher, Harari, Paul M, Csoszi, Tibor, Cernea, Dana, O'Brien, Paul, Hanley, William D, Kapp, Amy V, Anderson, Maria, Penuel, Elicia, McCall, Bruce, Pirzkall, Andrea, Vermorken, Jan B

Volltext

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors von Tran, Bao-Tram Thi, Gelin, Aurore, Durand, Sylvère, Texier, Matthieu, Daste, Amaury, Toullec, Clémence, Benihoud, Karim, Breuskin, Ingrid, Gorphe, Philippe, Garic, Florence, Brenner, Catherine, Le Tourneau, Christophe, Fayette, Jérôme, Niki, Toshiro, David, Muriel, Busson, Pierre, Even, Caroline

Volltext

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME von Chevalier, Thomas, Daste, Amaury, Saada‐Bouzid, Esmaa, Loundou, Anderson, Peyraud, Florent, Lambert, Tiphaine, Le Tourneau, Christophe, Peyrade, Frédéric, Dupuis, Charlotte, Alfonsi, Marc, Fayette, Jérôme, Reure, Juliette, Huguet, Florence, Fakhry, Nicolas, Toullec, Clémence, Salas, Sébastien

Volltext

Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma von Karabajakian, Andy, Garrivier, Thibaut, Crozes, Carole, Gadot, Nicolas, Blay, Jean-Yves, Bérard, Frédéric, Céruse, Philippe, Zrounba, Philippe, Saintigny, Pierre, Mastier, Charles, Fayette, Jérôme

Volltext